Investors
Recent News
Coronavirus company news summary – Color receives EUA for Covid-19 self-collection kit – Vivera Pharmaceuticals launches BIOZONE device
AXIM Biotechnologies has filed an Emergency Use Authorisation (EUA) application with the US Food and Drug Administration (FDA) for its first-in-class rapid diagnostic test for Covid-19. AXIM’s rapid diagnostic test is expected to be the market’s first Covid-19 rapid...
AXIM Biotechnologies files EUA with FDA for Covid-19 rapid diagnostic test for neutralising antibodies
AXIM’s rapid diagnostic test is expected to be the market’s first Covid-19 rapid diagnostic test for measuring levels of functional neutralising antibodies in a lateral flow assay format. AXIM Biotechnologies, an international healthcare solutions company targeting...
First-in-Class Rapid Diagnostic Test Measures COVID-19 Neutralizing Antibodies in Plasma and Serum
By HospiMedica International staff writers Posted on 17 Sep 2020 A new rapid diagnostic test is expected to be the market’s first COVID-19 rapid diagnostic test for measuring the levels of functional SARS-CoV-2 neutralizing antibodies in a lateral flow assay format....
BioWorld News to Note for Sept 16 2020
San Diego-based Axim Biotechnologies Inc., an international health care solutions company targeting oncological and COVID-19 research, has filed an emergency use authorization (EUA) application with the U.S. FDA for measuring COVID-19 neutralizing antibodies in plasma...
AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies
SAN DIEGO – September 16, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has filed an Emergency Use...
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
SAN DIEGO, August 24, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company has signed an exclusive...
Email Alerts
Stay informed and receive company updates straight to your inbox
